الصفحة الرئيسية>>Signaling Pathways>> Cell Cycle/Checkpoint>> Microtubule/Tubulin>>Combretastatin A1

Combretastatin A1 (Synonyms: CA1)

رقم الكتالوجGC43300

Combretastatin A1 هو مثبط بلمرة الأنابيب الدقيقة التي ترتبط بموقع الارتباط بالكولشيسين في التوبولين. يثبط Combretastatin A1 مسار Wnt / β-catenin من خلال إلغاء بلمرة التوبولين بوساطة تعطيل AKT. يعرض Combretastatin A1 تأثيرات مضادة للأورام ومضادة للأوعية الدموية.

Products are for research use only. Not for human use. We do not sell to patients.

Combretastatin A1 التركيب الكيميائي

Cas No.: 109971-63-3

الحجم السعر المخزون الكميّة
5mg
102٫00
متوفر
10mg
163٫00
متوفر
25mg
357٫00
متوفر
50mg
591٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Combretastatin A1 is a cis-stilbene originally isolated from C. caffrum that inhibits microtubule assembly (ID50 = 2 µM) by binding to the colchicine binding site on β-tubulin. It inhibits proliferation of hepatocellular carcinoma (IC50s = 9.2-728.2 nM) and other carcinoma cell lines (IC50s = 12.2-2,247 nM). Combretastatin A1 increases apoptosis of HepG2 cells in a GSK3β-dependent manner by decreasing the levels of MCL-1 and β-catenin. It inhibits tumor growth in a hepatocellular carcinoma mouse xenograft model when administered at doses of 2 or 4 mg/kg for 4 weeks. It also enhances the effects of carboplatin , paclitaxel , and cisplatin in murine models of cancer. Combretastatin A1 decreases functional vascular volume within hours in a well-vascularized murine colon adenocarcinoma model.

مراجعات

Review for Combretastatin A1

Average Rating: 5 ★★★★★ (Based on Reviews and 33 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Combretastatin A1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.